HeartSciences Statistics
Total Valuation
HeartSciences has a market cap or net worth of $8.01 million. The enterprise value is $8.48 million.
Important Dates
The last earnings date was Monday, March 16, 2026, after market close.
| Earnings Date | Mar 16, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
HeartSciences has 3.18 million shares outstanding. The number of shares has increased by 152.81% in one year.
| Current Share Class | 3.18M |
| Shares Outstanding | 3.18M |
| Shares Change (YoY) | +152.81% |
| Shares Change (QoQ) | +13.73% |
| Owned by Insiders (%) | 3.74% |
| Owned by Institutions (%) | 7.74% |
| Float | 3.07M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 923.56 |
| Forward PS | 11.21 |
| PB Ratio | 3.02 |
| P/TBV Ratio | 14.91 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 977.79 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.19, with a Debt / Equity ratio of 1.46.
| Current Ratio | 1.19 |
| Quick Ratio | 0.80 |
| Debt / Equity | 1.46 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -11.05 |
Financial Efficiency
Return on equity (ROE) is -382.32% and return on invested capital (ROIC) is -86.30%.
| Return on Equity (ROE) | -382.32% |
| Return on Assets (ROA) | -73.51% |
| Return on Invested Capital (ROIC) | -86.30% |
| Return on Capital Employed (ROCE) | -237.30% |
| Weighted Average Cost of Capital (WACC) | 16.66% |
| Revenue Per Employee | $578 |
| Profits Per Employee | -$565,687 |
| Employee Count | 15 |
| Asset Turnover | 0.00 |
| Inventory Turnover | 0.01 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -15.07% in the last 52 weeks. The beta is 2.45, so HeartSciences's price volatility has been higher than the market average.
| Beta (5Y) | 2.45 |
| 52-Week Price Change | -15.07% |
| 50-Day Moving Average | 2.86 |
| 200-Day Moving Average | 3.21 |
| Relative Strength Index (RSI) | 46.02 |
| Average Volume (20 Days) | 10,692 |
Short Selling Information
The latest short interest is 32,498, so 1.02% of the outstanding shares have been sold short.
| Short Interest | 32,498 |
| Short Previous Month | 37,981 |
| Short % of Shares Out | 1.02% |
| Short % of Float | 1.06% |
| Short Ratio (days to cover) | 3.42 |
Income Statement
In the last 12 months, HeartSciences had revenue of $8,669 and -$8.49 million in losses. Loss per share was -$4.03.
| Revenue | 8,669 |
| Gross Profit | 5,021 |
| Operating Income | -7.80M |
| Pretax Income | -8.49M |
| Net Income | -8.49M |
| EBITDA | -7.77M |
| EBIT | -7.80M |
| Loss Per Share | -$4.03 |
Full Income StatementBalance Sheet
The company has $3.40 million in cash and $3.87 million in debt, with a net cash position of -$470,096 or -$0.15 per share.
| Cash & Cash Equivalents | 3.40M |
| Total Debt | 3.87M |
| Net Cash | -470,096 |
| Net Cash Per Share | -$0.15 |
| Equity (Book Value) | 2.65M |
| Book Value Per Share | 0.83 |
| Working Capital | 829,925 |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$7.34 million and capital expenditures -$3,554, giving a free cash flow of -$7.34 million.
| Operating Cash Flow | -7.34M |
| Capital Expenditures | -3,554 |
| Depreciation & Amortization | 28,546 |
| Net Borrowing | 2.30M |
| Free Cash Flow | -7.34M |
| FCF Per Share | -$2.31 |
Full Cash Flow StatementMargins
| Gross Margin | 57.92% |
| Operating Margin | -89,939.57% |
| Pretax Margin | -97,880.97% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
HeartSciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -152.81% |
| Shareholder Yield | -152.81% |
| Earnings Yield | -105.98% |
| FCF Yield | -91.73% |
Analyst Forecast
The average price target for HeartSciences is $8.00, which is 218.22% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $8.00 |
| Price Target Difference | 218.22% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 17, 2024. It was a reverse split with a ratio of 1:100.
| Last Split Date | May 17, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:100 |
Scores
HeartSciences has an Altman Z-Score of -17.75 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -17.75 |
| Piotroski F-Score | 2 |
